Patents by Inventor Alec Lebsack

Alec Lebsack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic amides as modulators of TRPA1
    Patent number: 8614201
    Abstract: Certain heterocyclic amide compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPA1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: December 24, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Didier Jean-Calude Berthelot, Henricus Jacobus Maria Gijsen, Mirko Zaja, Jason Rech, Alec Lebsack, Bryan Branstetter, Wei Xiao, J. Guy Breitenbucher
  • Quinoline or isoquinoline substituted P2X7 antagonists
    Patent number: 8431704
    Abstract: The present invention is related to novel compounds of formula (I) having P2X7 antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans. (I).
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: April 30, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Christopher John Love, Joseph Elisabeth Leenaerts, Ludwig Paul Cooymans, Donald Alec Lebsack, Bryan James Branstetter, Jason Christopher Rech, Elizabeth Ann Gleason, Jennifer Diane Venable, Danielle Wiener, Deborah Margaret Smith, James Guy Breitenbucher
  • HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1
    Publication number: 20120083474
    Abstract: Certain heterocyclic amide compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPA1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.
    Type: Application
    Filed: June 4, 2010
    Publication date: April 5, 2012
    Inventors: Didier Jean-Claude Berthelot, Henricus Jacobus Maria Gijsen, Mirko Zaja, Jason Rech, Alec Lebsack, Wei Xiao, Bryan Branstetter, Guy J. Breitenbucher
  • Tetrahydro-pyrimidoazepines as modulators of TRPV1
    Publication number: 20070225275
    Abstract: Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be-administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.
    Type: Application
    Filed: March 21, 2007
    Publication date: September 27, 2007
    Inventors: Brett Allison, Bryan Branstetter, James Breitenbucher, Michael Hack, Natalie Hawryluk, Alec Lebsack, Kelly McClure, Jeffrey Merit
  • Vla-R Antagonists
    Publication number: 20070219252
    Abstract: Compounds of Formula (I) are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn's disease, multiple sclerosis, asthma, and rheumatoid arthritis.
    Type: Application
    Filed: August 12, 2005
    Publication date: September 20, 2007
    Inventors: Weichao Chen, Alec Lebsack, Benito Munoz, Shankar Venkatraman, Bowei Wang
  • Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain
    Publication number: 20070213338
    Abstract: The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders—such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal and other diseases. The present invention is also directed to novel triazolo-pyridazine compounds that selectively bind to ?2?-1 subunit of Ca channels.
    Type: Application
    Filed: October 15, 2004
    Publication date: September 13, 2007
    Inventors: Alec Lebsack, Benito Munoz, Richard Pracitto, Shankar Venkatraman, Bowei Wang, Janet Gunzner